Findings

What do systematic reviews say?

163 questions · 169 findings · 21 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 3%GRADE not reported 5 · 3%Very low 29 · 17.2%Low 47 · 27.8%Moderate 49 · 29%High 34 · 20.1%

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

Short‐term adverse events · women with breast cancer and one to three positive lymph nodes

1 finding from 1 review

Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

Long‐term adverse events · women with breast cancer and one to three positive lymph nodes

1 finding from 1 review

Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

QoL · women with breast cancer and one to three positive lymph nodes

1 finding from 1 review

Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

CBT vs control

Depression Hospital Anxiety and Depression Scale (HADS) or Beck Inventory Score (HADS score range from 0 to 21 and Beck Inventory Score range from 0 to 63) · Women with non‐metastatic breast cancer

1 finding from 1 review

Psychological interventions for women with non‐metastatic breast cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
27 studies · 3321 participants
Low

CBT vs control

Anxiety · Women with non‐metastatic breast cancer

1 finding from 1 review

Psychological interventions for women with non‐metastatic breast cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 2702 participants
Low

CBT vs control

Mood disturbance Profile of mood state (higher score indicates more mood disturbance, score range from 0 to 200) · Women with non‐metastatic breast cancer

1 finding from 1 review

Psychological interventions for women with non‐metastatic breast cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 2276 participants
Low

CBT vs control

QoL · Women with non‐metastatic breast cancer

1 finding from 1 review

Psychological interventions for women with non‐metastatic breast cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
20 studies · 1747 participants
Low

CBT vs control

Stress 1 month · Women with non‐metastatic breast cancer

1 finding from 1 review

Psychological interventions for women with non‐metastatic breast cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 564 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Change in pain from baseline to end of intervention · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 183 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Grip strength ‐ Vitamin D · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Effect on breast cancer‐specific quality of life (BCS‐QoL) · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 147 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Health‐related quality of life (HRQoL) · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 208 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Safety of systemic therapies for the treatment of AIMSS · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1250 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in grip strength · women with early breast cancer

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 1.08 [0.37, 3.17]
1 study · 137 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Safety of systemic therapies for the treatment of AIMSS · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 344 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Effect on discontinuation of aromatase inhibitors (AI) · women with early breast cancer

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 0.16 [0.01, 2.99]
1 study · 147 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Effect on breast cancer‐specific quality of life (BCS‐QoL) · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Incidence of AIMSS · women with early breast cancer

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 0.82 [0.63, 1.06]
2 studies · 240 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in pain from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1099 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in stiffness from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 295 participants
Very low